Emergent BioSolutions, Inc. (EBS)
| Market Cap | 4.92B |
| Revenue (ttm) | 1.56B |
| Net Income (ttm) | 305.10M |
| Shares Out | 52.70M |
| EPS (ttm) | 5.67 |
| PE Ratio | 16.28 |
| Forward PE | 12.02 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $92.31 |
| Previous Close | $90.87 |
| Change ($) | 1.44 |
| Change (%) | 1.58% |
| Day's Open | 92.60 |
| Day's Range | 86.16 - 92.99 |
| Day's Volume | 726,433 |
| 52-Week Range | 46.37 - 137.61 |
Emergent CEO Bob Kramer told CNBC that the company has infrastructure in place to produce Johnson & Johnson and AstraZeneca vaccines around the clock.
GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the follow...
The stock price of Emergent Biosolutions, a biopharmaceutical company focused on vaccines and antibody therapeutics for infectious diseases, and opioid overdoses, has seen a 17% drop over the ...
With the trading day more than halfway over, the broad markets have pushed higher, seemingly recovering from Tuesday.
With the trading day more than halfway over, the broad markets were sliding into the weekend.
Emergent's (EBS) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Sales of contract development and manufacturing services rise.
Shares of Emergent BioSolutions (NYSE:EBS) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 133.76% over the past year to $3.6...
GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2020. The Company also ...
These stocks would be buys even without the pandemic.
GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the fi...
Shares of Humanigen Inc. were down 2.5% in trading on Monday after it announced a contract development and manufacturing deal with Emergent BioSolutions Inc. for its experimental COVID-19 trea...
GAITHERSBURG, Md. & BURLINGAME, Calif.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered i...
Emergent BioSolutions remains well insulated from peers, with key COVID-19 vaccine drivers and exposure to adjacent specialty markets in public crises prevention. Additional drivers in contrac...
Emergent Biosolutions CEO discusses role in helping to bring coronavirus vaccines to market
Emergent Biosolutions CEO Bob Kramer joined Jim Cramer on "Mad Money" to give an update on the coronavirus vaccine manufacturing front.
Emergent (EBS) tightens revenue view for 2020 and expects a consistent rise in sales of contract development and manufacturing services provided to other companies.
GAITHERSBURG, Md., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced its financial forecast for 2021 and selected preliminary unaudited financial results ...
Emergent Biosolutions (EBS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Emergent Biosolutions (EBS) closed the most recent trading day at $97.97, moving +1.01% from the previous trading session.
Is (EBS) Outperforming Other Medical Stocks This Year?
This biotech is about to tackle an enormous market opportunity as coronavirus vaccines receive regulatory clearance.
GAITHERSBURG, Md., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the foll...
GAITHERSBURG, Md. and NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System today announced initiation of the clinical program to evaluate...
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?
Investors have been selling these stocks, but patient investors should take advantage of the opportunity.
Could these stocks be winners regardless of which coronavirus vaccine comes out on top?
Is Emergent BioSolutions (EBS) a great pick from the value investor's perspective right now? Read on to know more.
While profitability came in above estimates, the company missed big on the top line.
Emergent (EBS) beats on earnings in Q3 while revenues miss estimates. Total product sales fall year over year and the company tightens its revenue guidance.
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2020 Results - Earnings Call Transcript
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 6.83% and -14.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...
On Emergent's (EBS) upcoming third-quarter earnings call, investors will focus on the company's recent CDMO collaborations to help partners manufacture a vaccine against COVID-19.
Emergent Biosolutions (EBS) closed the most recent trading day at $90.77, moving -0.55% from the previous trading session.
Emergent BioSolutions has key niche differentiators that strengthen the operating model, with exposure to defence & public health threats. They hold the only FDA approved anthrax vaccine in th...
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is (EBS) Outperforming Other Medical Stocks This Year?
In the latest trading session, Emergent Biosolutions (EBS) closed at $99.55, marking a +1.86% move from the previous day.
Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.
GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 5, 2020 at 5:00 pm (Eastern Time) to discuss the f...
Blame it on Johnson & Johnson's pause of a late-stage study of its coronavirus vaccine candidate.
Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.
Forget politics and a pandemic. The outlook for these stocks keeps getting better, and analysts can't keep up.
GAITHERSBURG, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of the Phase 3 clinical trial that will evaluate plasma-derived therap...
Is (EBS) Outperforming Other Medical Stocks This Year?
Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.
Emergent BioSolutions has been struggling lately, but the selling pressure may be coming to an end soon.
Emergent Biosolutions stock has rallied 111% since late March (vs. about 53% for the S&P 500) to its current level around $105.
Is (EBS) Outperforming Other Medical Stocks This Year?
In case of the S&P 500, whenever the index has gained more than 5% in August, September gains averaged 1.4%.
Strong economic data and positive developments in coronavirus vaccine trials have helped stocks overcome the coronavirus slump. Here are five stocks that can make the most
About EBS
Emergent BioSolutions, a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a chol... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Nov 15, 2006 |
| CEO Robert Kramer | Employees 2,200 |
| Stock Exchange NYSE | Ticker Symbol EBS |
Financial Performance
In 2020, EBS's revenue was $1.56 billion, an increase of 40.63% compared to the previous year's $1.11 billion. Earnings were $305.10 million, an increase of 459.82%.
Analyst Forecasts
According to 7 analysts, the average rating for EBS stock is "Buy." The 12-month stock price forecast is 118.50, which is an increase of 28.37% from the latest price.